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ABSTRACT 
A simple liquid-liquid extraction procedure and quantification by high-performance liquid 
chromatography (HPLC) method coupled to a diode-array detector (DAD) of genistein (GEN) 
was developed in various mouse biological matrices. 7-ethoxycoumarin was used as internal 
standard (IS) and peaks were optimally separated using a Kinetex C18 column (2.6 µm, 150 mm 
X 2.10 mm I.D.) at 40 ºC with an isocratic elution of mobile phase with sodium dihydrogen 
phosphate 0.01M in water at pH 2.5 and methanol (55:45, v/v), at a flow rate of 0.25 mL/min. 
The injection volume was 10 µL. In all cases, the range of GEN recovery was higher than 61%. 
The low limit of quantification (LLOQ) was 25 ng/mL. The linearity of the calibration curves 
was satisfactory in all cases as shown by correlation coefficients >0.996. The within-day and 
between-day precisions were <15% and the accuracy ranged in all cases between 90.14 and 
106.05%. This method was successfully applied to quantify GEN in liver, spleen, kidney and 
plasma after intravenous administration of a single dose (30 mg/Kg) in female BALB/C mice.  
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1. INTRODUCTION 
Nowadays, biomedicine is returning to nature in order to find molecules that could have 
interesting applications both in human and in animal health. An example of these are 
polyphenolic compounds, which are the most abundant natural source of antioxidants (fruits, 
vegetables, legumes and plant leaves). Moreover, genistein (GEN) [1] is the principal soy 
isoflavone found in nature, together with daidzein and glycitein. Soy is a very important 
constituent in Asian and vegetarian nutrition [2], and represents a huge economic impact on 
society. Additionally, epidemiological studies suggest that GEN helps to protect against cancer 
[3-7], cardiovascular diseases [8], osteoporosis [9], age-related diseases [10] and inflammation 
processes [11]. Probably the most attractive activity of this bioflavonoid is its promising 
chemopreventive activity, which works by inducing either G2/M or G0/G1 cell cycle arrest 
depending on the cell line [12-14]. Interestingly, this molecule does not interact with DNA, with 
the consequent absence of severe secondary effects when compared to current chemotherapy. 
Despite the high potential interest of GEN in antitumor therapy, further experiments are 
required before proceeding to clinical use, starting with cells, moving on to rodents and finally 
to humans.  
Although GEN is a molecule that has been fully studied in other fields, such as agronomy or 
plant physiology, it is still novel in the biomedical field, and there are very few publications 
related to its quantification in biological matrices.  
Regarding the agronomic or nutritional aspects, it is important to characterize soy content, 
explain how to harvest it [15-17] and how to enrich nutritional products designed for 
vegetarians [18], as nowadays there is a tendency in human dietetics towards vegetable-friendly 
food. Some analytical methods have been reported so far for the quantification of isoflavonoids, 
mainly based on liquid chromatography coupled to a tandem mass spectrometry (MS/MS) 
detector [16, 17].  
Concerning the quantification of GEN in biological matrices, the few reported studies deal with 
its extraction and quantification in human plasma/serum and urine matrices based on HPLC-MS 
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 using either complex solid-phase [19, 20] or liquid-liquid extraction procedures [21]. Liquid-
liquid extraction methods were more or less time-consuming, since they involved agitation, 
evaporation and reconstitution steps. Other studies have proposed the usage of enzymes, such as 
β-glucuronidase, for the quantification of total (free and metabolized) GEN in mouse plasma 
and serum [22-25]. To the best of our knowledge, no validated quantification method of GEN 
has been reported so far regarding mouse tissues HPLC methods coupled to a DAD detector. 
However, Supko validated an HPLC-UV method for GEN quantification in plasma and urine 
with identification of GEN peaks by HPLC-MS in mouse matrices [26]. HPLC-MS has been 
used to quantify total GEN in rat serum [27, 28] and in rat endocrine-responsive tissues (brain, 
liver, mammary, ovary, prostate, testis, tyroid and uterus) [28], with a LOQ near to 5 ng/g. 
Apart from the previously mentioned methods, Feng studied the pharmacokinetic profile of 
GEN tablets in beagle dog plasma [29]. 
Here we describe a simple liquid-liquid extraction procedure followed by a sensitive and 
accurate HPLC method coupled with a diode-array detector (DAD) to quantify GEN in different 
mouse biological matrices, including plasma, spleen, kidney and liver. Moreover, the 
pharmacokinetic and biodistribution of GEN in different organs were investigated in female 
BALB/C mice by using the method developed here. 
 
2. EXPERIMENTAL 
2.1. Chemicals and reagents 
GEN was purchased from LC Laboratories (USA). The internal standard (IS), 7-
ethoxycoumarin, was purchased from Sigma-Aldrich (Spain). All the reagents, including HPLC 
grade methanol, polyethylene glycol 400, dimethylsulfoxide, tert-butyl methyl ether and 
orthophosphoric acid were acquired from Merck (Germany). Sodium dihydrogen phosphate was 
acquired from Fagron (Spain). Phosphate buffer saline pH 7.4 1x (PBS) for organ 
homogenization was purchased from Gibco (USA). 
 
2.2. Standard solutions, calibrator and quality control samples 
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 Stock solutions of GEN and IS (concentration 1 mg/mL) were prepared by accurately weighing 
the required amounts into separate volumetric flasks and dissolving them in methanol. Standard 
solutions were prepared by diluting the stock solutions with methanol. For the calibrators and 
quality control samples (QC), serial dilutions were made with methanol to provide GEN 
intermediate stock solutions of 250, 500, 750, 1000, 2000, 2500, 5000, 10000, 12500, 20000 
and 25000 ng/mL, and the IS was diluted up to 10000 ng/mL with methanol. Calibration 
samples were prepared in the different matrices using 10 μL of 250, 500, 1000, 2000, 2500, 
5000, 10000, and 25000 ng/mL GEN intermediate stock solutions and 90 μL of each biological 
matrix to give a final range of 25–2500 ng/mL. QC were prepared in the same way using the 
intermediate stock solutions of 750 (QC2), 12500 (QC3) and 20000 (QC4) ng/mL. All the 
solutions were stored at -80 ºC until use. 
 
2.3. Sample pretreatment 
2.3.1. Plasma samples 
One hundred µL of sample (calibrators, QC, and kinetic samples) were mixed with 90 µL of IS 
solution followed by 1-min vigorous shaking. Then, 200 µL of sodium dihydrogen phosphate 
0.01 M pH 2.5 were added to the prior mixture, and mixed by a 10-sec homogenization. After 
this, 1 mL of tert-butyl methyl ether was added in order to extract GEN from the total sample 
and the mixture was vigorously vortexed during 1 min under the extraction hood. Later, the 
samples were centrifuged at 1 ºC for 10 min at 300 g. The supernatant was carefully put inside 
glass tubes, which were later evaporated in a vortex evaporator (Labconco 4322000, Fisher 
Scientific, USA) at 40 ºC for 15 min. Finally, 100 µL of mobile phase were added to the prior 
evaporated sample tubes and vigorously stirred for 1 min. The final solution was put in 300 µL 
HPLC glass vials for analysis. 
 
2.3.2. Tissue samples: liver, spleen and kidney 
Each organ was weighed and homogenized with 1 mL of PBS. Then, 100 µL of the tissue 
sample (calibrator, QC or tissue sample) were mixed with 10 µL of IS solution by 1-min of 
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 vigorous shaking. The next steps were identical to those followed in plasma preparation samples 
(see plasma samples section). 
 
2.4. Chromatographic system 
GEN concentrations were determined using a HPLC system Agilent Technologies Series 1200 
equipped with an Infinity Diode Array Detector and controlled by ChemStation for LC 3D 
systems (Agilent Technologies, USA). The analytical column was a Kinetex C18 2.6 µm, 150 
mm x 2.10 mm I.D. (Phenomenex, USA) protected by guard cartridge precolumn with the same 
packing material. 
The composition of the mobile phase was a mixture of sodium dihydrogen phosphate 0.01 M in 
water at pH 2.5 with methanol at a ratio of 55:45 (v/v). The flow rate was 0.25 mL/min and the 
injection volume was 10 µL. Methanol was used as needle wash after each injection. Column 
oven temperature and auto sampler temperature were set to 40±3 °C and 4±2 °C, respectively. 
GEN and IS were detected by UV absorbance at the wavelengths of 260 and 320 nm, 
respectively. The total analysis time was 13 min. 
 
2.5. Validation of the method  
The assay was validated following the Food and Drug Administration (FDA) Guidelines on 
Bioanalytical Method Validation [30]. Specificity, linearity, precision and accuracy, recovery 
and stability were the parameters evaluated. 
 
2.5.1. Specificity and selectivity 
One lot of blank plasma and blank tissues, together with plasma and tissue samples from 
BALB/C mice, was tested for interferences. The data of the chromatograms were processed and 
the integrated response should not exceed 20% of the average integrated response of the LLOQ 
of GEN or 5% of the integrated response of IS. 
 
2.5.2. Linearity and limit of quantification (LLOQ) 
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 A total of 5 calibration curves were prepared in plasma and in the different tissues and measured 
during 5 runs. Calibration curves were obtained by fitting the peak area ratios to a weighted 
(1/x) least squares regression model. The calibration curve should have a correlation coefficient 
(r) equal or higher than 0.996. The acceptance criterion for each back-calculated standard 
concentration was 15% deviation from the nominal value, except for LLOQ, which was set at 
20%. At least 67% of non-zero standard should meet the above criteria including LLOQ and 
upper limit of quantification. 
LLOQ was investigated by analyzing 5 replicates of spiked samples at a concentration of 25 
ng/mL with acceptable precision. The signal-to-noise ratio (S/N) of LLOQ was at least 10 and 
the values for precision and accuracy were less than 20%. 
 
2.5.3. Precision, accuracy and recovery 
The accuracy and precision of the method were determined for the QC samples during 5 
consecutive runs. In the first run, all QC concentration levels were analyzed 5 times (within-run 
accuracy and precision). During the 5 runs, a single sample of each level was analyzed 
(between-run precision). Mean accuracy and within-run precision (coefficient of variation) were 
calculated from the results (n=5) of the first run. Between-run accuracy precision was 
calculated from the results (n=20) of the samples of the first run and the samples of the second 
and third runs. 
The acceptability criteria of the data were accuracy within ±15% S.D. (standard deviation) and 
precision ±15% R.S.D., as previously reported for analytical methods, except for the LLOQ, 
which reached a maximum of 20%. 
The GEN recovered from the different matrices was determined by QC2 (75 ng/mL), QC3 
(1250 ng/mL) and QC4 (2000 ng/mL), as well as the IS (1000 ng/mL) (n=4). Absolute 
recoveries were calculated by comparing the signal area (GEN/IS ratio) of the spiked samples 
obtained against the equivalent concentrations without extraction. 
 
2.5.4. Dilution integrity 
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 A dilution integrity validation of plasma samples was carried out on samples with GEN above 
the upper limit of quantification, the dilutions being 1:10 in plasma to obtain a theoretical GEN 
concentration of 2000 ng/mL. Precision and accuracy were determined for the samples by 
analyzing them against calibration curve standards. Dilutional integrity was considered 
acceptable if the precision and accuracy values of the replicate of the diluted samples (n=4) 
varied less than 15%. 
 
2.5.5. Stability 
The stability of GEN in QC2 and QC4 samples in all matrices was determined in the auto-
sampler (4 ºC) after 24 and 48 h and compared with the initial concentration. The analyte was 
considered stable in the extracts of each biological matrix if 85–115% of the reference 
concentration was obtained. No further stability experiments were performed because the 
conditions had already been tested in human serum [21] and mouse plasma [26, 31].  
 
2.6. Applicability of the method 
To demonstrate its applicability, the method was successfully applied to the pharmacokinetic 
evaluation of GEN in plasma, as well as its determination in kidney, spleen and liver. All 
experimental procedures were reviewed and approved by the Animal Experimentation Ethics 
Committee of the University of Navarra (Spain). The study was performed using female 
BALB/mice (6 to 8 weeks old; 20±1 g body weight) purchased at Harlan (Harlan Ibérica, 
Spain). Mice were housed in cages and maintained at 22-25 ºC and 20% relative humidity with 
a 12 h light/dark cycle. Remarkably, the mice feed had traces of GEN. Therefore, 12 h prior to 
the experiment start, mice were deprived from food ingestion and had drinking water ad libitum. 
A single dose of 100 µL of a homogeneous GEN solution (30 mg/Kg) containing 10% 
dimethylsulfoxide, 25% polyethylene glycol 400 and 65% of water for injection was 
intravenously (i.v) administered to 6 animals. Blood samples were collected at 5, 15, 30, 60, 120 
and 240 min in EDTA-coated tubes to avoid blood coagulation. Just after blood extraction, the 
samples were centrifuged at 5000 g for 10 min at 4 ºC and plasma was kept at –80 ºC until 
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 sample analysis. Four hours after the start of the experiment, mice were sacrificed and their 
kidneys, spleens and livers were removed, homogenized with 1 mL of PBS pH 7.4 and kept at –
80 ºC until sample analysis.  
 
3. RESULTS AND DISCUSSION 
3.1. Development of the analytical method 
A simple and accurate HPLC method has been developed for the quantification of GEN in 
different biological matrices. Here, different parameters that influence effective separation of 
the molecule of study from the biological matrices will be further discussed, such as the 
structure of GEN and IS, the composition and pH of the mobile phase, the temperature and the 
analytical column. 
When regarding the separation and quantification techniques, despite the HPLC-MS procedure 
previously reported for the analysis of GEN in biological samples, including plasma, no HPLC 
methods coupled to DAD detection have been reported so far for GEN quantification in mouse 
plasma and tissues.  
GEN and IS (Figure 1) are two molecules containing double bonds in their structure, being 
possible their detection in HPLC-UV. Both molecules exhibit a similar chemical structure 
containing a benzopyranone fraction, as well as, comparable shape and rigidity. Their aromatic 
cycles bestow a lack of spin due to their rigid conformation. 
A very important parameter in the method development was the pH of the mobile phase, as 
GEN possessed three hydroxyl groups that could be deprotonated depending on the pH value 
(GEN pka1=7.2; pka2=10.0; pka3=13.1) [32]. In order to avoid the presence of partially 
deprotonated forms of GEN, pH of the mobile phase was fixed to pH<4.  
Several compositions of the mobile phase were tested, including some mixtures of 
methanol/sodium phosphate dibasic solution, methanol/formic acid and acetonitrile/formic acid, 
using both isocratic and gradient elutions. An efficient separation of IS and GEN for all the 
matrices studied was achieved, using isocratic elution of methanol/sodium phosphate dibasic 
solution. In order to determine the optimal separation, different proportions of sodium 
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 phosphate dibasic solution/methanol were used. The selectivity of the method was strongly 
influenced by the sodium phosphate dibasic solution/methanol ratio, as higher amounts of 
methanol (58% v/v) were associated with GEN as the first peak, whereas lower amounts of 
methanol (45% v/v) were associated with IS as the first peak.  
Alongside the mobile phase, temperature was a crucial parameter for obtaining an optimal 
separation. Different temperatures (40, 50 and 60 ºC) were studied together with various mobile 
phase proportions. For instance, the method selectivity of GEN and IS with the selected mobile 
phase methanol/sodium phosphate dibasic solution 45:55 (v/v) changed dramatically with 
temperature. Although higher temperatures lead to shorter analysis time, the selected method 
was set at 40 ºC. This lower temperature allows a more efficient separation of the many 
endogenous compounds contained in biological matrices, avoiding interference with the GEN 
and IS compounds.  
To find out the best separation method, several columns were tested, including RP-C18 3 µm 
Gemini NX reverse phase 150 x 2.0 mm (Phenomenex) and RP-C18 5 µm Durashell 150 mm x 
4.6 mm (Agela Technologies Inc). Recently, an efficient separation of several isoflavones has 
been reported by using the Gemini column using a flow rate of 0.15 mL/min in 80-min analysis 
[33]. The Gemini column led to suitable separation of GEN in 15-min chromatograms when 
looking at the plasma gradient method (GEN retention time ~ 3.3 min). A good peak resolution 
in convenient times (retention time ~ 6 min) was also possible using the Durashell column, 
which has a larger diameter (4.6 vs. 2.0 µm), larger particle size (5 vs. 3 µm) and works at 6-
fold higher flow rates than the Gemini column. Although both columns were well-adapted to 
separate GEN mixtures in biological matrices, the use of a core-shell technology package 
enabled us to obtain robust symmetrical peaks, as well as being a more sensitive method, 
approximately 10 times better than the Durashell column and 5 times better than the Gemini 
column, reaching a LLOQ of 25 ng/mL. 
 
3.2. Chromatographic conditions 
10 
 
 Good separations were obtained under the chromatographic conditions indicated in the 
Experimental Section. Figure 2 shows the chromatograms of blank samples, spiked plasma and 
tissue samples with IS and GEN at the LLOQ analyzed by the HPLC-DAD technique. The 
retention times for GEN and IS were: 9.65±0.01 and 8.72±0.01 min for plasma, 9.19±0.01 and 
8.35±0.01 min for liver, 10.43±0.13 and 9.19±0.03 min for spleen and 10.25±0.13 and 
8.98±0.07 min for kidney.  
 
3.3. Sample preparation 
A crucial step in determining GEN from biological matrices concerns the previous sample 
treatment since a good extraction procedure would lead to high recovery yields together with 
easier separation and therefore, quantification. Also, an optimal sample preparation lengthens 
the life of an analytical column and leads to lower drug interferences with other compounds of 
the biological matrix.  
The recovery yield of the sample extraction procedure is good. It might be thought that a 
method with recoveries ranging from 61.25-88.15% could be improved. However, when 
compared to other liquid-liquid extraction methods, our recovery range is similar. Concretely, 
previous studies in human plasma showed mean recovery values of 57.58% [21] and between 
40-60% [34], values slightly lower to the here described method, in which the lowest recovery 
values were of 61%. However, Supko achieved mean recovery values of almost 100% in mouse 
plasma after an exhaustive extraction method [26] when compared to ours. Solid-phase 
extraction methods without containing enzymes for the quantification of GEN and other 
isoflavone metabolites have shown recoveries around 78.8% in human plasma [31]. 
 
3.4. Validation 
3.4.1. Specificity and selectivity 
Biological matrices were tested with the aim of observing any possible interference with GEN 
and the compounds already present in the sample. The chromatographic conditions developed 
for each matrix contributed to a significant resolution of GEN and IS peaks, together with a high 
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 specificity and selectivity. Moreover, the data showed that the peaks were reproducible due to a 
robust and reliable separation method. As shown in Figure 2, the chromatograms did not exhibit 
any peak interfering with GEN or IS in any matrix.  
 
3.4.2. Linearity and LLOQ 
The linearity of the method was checked for all mouse matrices. All the biological matrices 
studied in this article were linear from 25 to 2500 ng/mL of GEN, the r values ranging from 
0.996-0.998. The regression curve equations for the different mouse matrices (n=5) are shown 
in Table 1. Also, the back-calculated calibrator concentrations from these regression curve 
equations did not exceed 15% of the theoretical value. For all the biological matrices tested 
here, the LLOQ was 25 ng/mL, paving the way for the development of future GEN 
pharmacokinetic and biodistribution tests at therapeutic doses of GEN. In this case, the 
previously validated method by Supko in mouse plasma is comparable to the here-developed 
method [26]. However, no data regarding HPLC-UV validation methods in mouse tissues have 
been found, being the present study only comparable to already published HPLC GEN 
quantification methods coupled to a MS detector [23, 31]. In these cases, LLOQ values of 0.1 
ng/mL [19] and 1 ng/mL [21] in human serum, 8.5 ng/mL in human plasma [20] were reached. 
The method here developed coupled to a DAD reached an acceptable LLOQ (25 ng/mL), even 
when it was compared with methods previously developed using HPLC coupled to a MS/MS 
detector and UV.  
 
3.4.3. Precision, accuracy and recovery 
The between- and within-day precision and accuracy values for the 4 biological matrices are 
displayed in Table 2. The precision values ranged from 2.36 to 10.24% in the case of plasma, 
6.27 to 10.37% in the case of liver, 5.87 to 11.20% in the case of spleen and 5.35 to 9.87% in 
the case of kidney. Alongside these, the accuracy values ranged from -6.92 to 5.17% in the case 
of plasma, 0.81 to 6.05% in the case of liver, 9.86 to 4.62% in the case of spleen and -8.30 to 
3.76% in the case of kidney. All the data were within the FDA acceptance criteria (<15%). 
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 The range of recoveries of GEN found in plasma, liver, spleen and kidney ranged between 
61.25-88.15% for GEN, obtaining the highest values in plasma and the lowest in spleen. In the 
case of the IS, the recoveries ranged from 63.66-78.26% (Table 3). 
 
3.4.4. Dilution integrity 
Dilution integrity was evaluated at one dilution factor (1:10) for plasma samples (n=4). The 
values for precision and accuracy were respectively 6.78 and -4.99%, being within the 
acceptance limit of 15%. 
 
3.4.5. Stability 
The stability of GEN was analyzed after the extraction process. QC of 75 and 2000 ng/mL were 
studied at 24 and 48 h after storage in the autosampler (4 ºC). As Table 4 shows, all the 
precision and accuracy values were within the acceptance limit of 15%. Previous studies 
confirmed GEN stability of human serum samples in methanol/water (80:20; v/v) for 72 h at 4 
ºC and for two months at –20 ºC [21]. Also, the stability of GEN was confirmed in mouse 
plasma samples in methanol/0.05 M ammonium acetate buffer pH 4.7 (30:70; v/v) for 6.2 h at 
37 ºC and for one month at -16 and -68 ºC [26] and in acetonitrile/water (15:85; v/v) for 4 h at 
25 ºC, 8 h at 20 ºC, one week at -20 ºC and after 3 freeze/thaw cycles (-20 to 25 ºC) [31]. 
 
3.4.6. Application of the method: pharmacokinetic and biodistribution studies 
The applicability of the method was initially demonstrated in vivo by determining GEN 
concentrations in plasma, liver, spleen and kidney after the i.v. administration of 30 mg/Kg to 
female BALB/C mice (n=6). Figure 3 depicts the levels of GEN in plasma. A typical i.v. drug 
administration profile was observed, showing a biphasic profile. The Cmax (8500 ng/mL) was 
immediately achieved after i.v. administration (t=5 min), followed by a dramatic decrease in the 
levels until t=45 min, obtaining a concentration of approximately 750 ng/mL. After that time, 
GEN levels underwent a slower decrease until t=240 min, where the concentration observed 
was approximately 250 ng/mL. These results are in agreement with those obtained by Yang et 
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 al., in which immediately after i.v. administration of a dose of 20 mg/Kg, GEN showed a Cmax 
of 15600±5900 ng/mL, followed by a rapid and pronounced decrease of GEN levels until a 
plateau of 27 ng/mL that was reached after 6 h of the i.v. administration. The same profile was 
also observed by Andrade et al., the GEN levels being lower due to a smaller dose (1.2 mg/Kg) 
[35]. Moreover, Penza et al., studied the profile of GEN after the oral administration of a dose 
of 50 mg/Kg to mice while maintaining their normal food. In that study, it was observed that, 
after that dose was administered for three continuous days, the levels of GEN increased from 25 
to 459 ng/mL [22].  
Regarding the biodistribution of GEN, as seen in Figure 4, all the levels of the soy isoflavone 
were detectable in liver and kidney. However, in the case of spleen, in only one case were the 
levels quantifiable, being very close to the LLOQ of the method. Nonetheless, the mean levels 
seen in liver (2000 ng/g) were twice those of the mean levels in kidney (1000 ng/g), probably 
due to the hepatic metabolism of GEN.  
 
4. CONCLUSION 
A simple, accurate and robust HPLC method coupled to a DAD for the analysis of GEN was 
developed and validated. The method showed good extraction yield recoveries exceeding 61% 
in all matrices, being specific, accurate, precise and reproducible for the analysis of this soy 
isoflavone in mouse plasma, kidney, spleen and liver. Remarkably, it was possible to reach a 
LLOQ of 25 ng/mL using a HPLC coupled to a DAD system. Moreover, this method is valuable 
for the pharmacokinetic behavior of this bioflavonoid and its distribution in BALB/C mice. 
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Figure Legends 
Figure 1. Chemical structure for genistein and 7-ethoxycoumarin. 
Figure 2. Chromatograms of genistein (GEN) at λ= 260 nm and 7-ethoxycoumarin (IS) at λ= 
320 nm, for all the mouse biological matrices, being blank plasma (A1), blank liver (B1), blank 
spleen (C1) and blank kidney (D1) when compared to the LLOQ (25 ng/mL) in plasma (A2), 
liver (B2), spleen (C2) and kidney (D2). 
Figure 3. Pharmacokinetic profile of genistein (D=30 mg/Kg) in BALB/C female mice after 
intravenous administration. 
Figure 4. Biodistribution of genistein (D=30 mg/Kg) in kidney, spleen and liver in BALB/C 
female mice 240 min after intravenous administration. 
 
 
17 
 
